Atopic Dermatitis

In this segment of his interview, Zirwas highlighted the use of JAK inhibitors such as upadacitinib, discussed safety, and touched on topical options for patients with eczema.

Zirwas described several highlights from his presentation on updates in managing atopic dermatitis, describing examples such as lebrikizumab and nemolizumab.

After his review on recent literature, Zirwas’s Maui Derm NP+PA Fall interview featured a discussion about the biggest unmet needs among patients.

Leo Pharma announced the availability of a single-dose autoinjector of tralokinumab for moderate-to-severe atopic dermatitis, approved by the FDA in June 2024.

These poster data highlight that atopic dermatitis treatment may be suboptimal in certain patients, demonstrating the necessity of additional effective therapy options.

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.

Experts on atopic dermatitis compare the safety profile of JAK inhibitors with traditional and more advanced treatments currently available for patients.

Nemolizumab shows early and sustained benefits in reducing itch and sleep disturbance in moderate-to-severe atopic dermatitis, per ARCADIA data.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

This is an overview of our upcoming Maui Derm NP+PA Fall 2024 Program conference coverage.

Eli Lilly’s announcement of the lebrikizumab-lbkz approval for patients 12 years of age and older follows positive findings from the ADvocate 1, ADvocate 2, and ADhere studies.

Multiple biomarkers and clinical background factors were linked to improved clinical outcomes after dupilumab therapy for AD.

In this analysis, an increased risk of allergy and eczema was associated with bread and thiamine intake increases during pregnancy.

In this survey, investigators sought to develop a definition for eczema flare which was patient-centered and based upon consensus.

These data may provide invaluable insights, given the lack of reliable methods for identifying newborns with increased risk of developing eczema.

These findings resulted from a systematic literature review highlighting the impact of stigma and lack of support on self-image for patients with eczema, psoriasis, HS, and other conditions.

A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.

Focusing on the complex pathophysiology of atopic dermatitis, Lindsay S. Ackerman, MD, FAAD, discusses the importance of looking beyond type 2 inflammation while treating patients.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

These data were presented at the European Society of Contact Dermatitis congress, with findings drawn from the CHECK and RWEAL studies on chronic hand eczema.

Dermatologists outline unmet needs in the treatment landscape for atopic dermatitis and discuss how to potentially improve the standard of care for patients with atopic dermatitis.

The panel provides comprehensive insights on treating atopic dermatitis and how recent advances have elevated standard-of-care treatment practices in dermatology practices.

These data suggest the necessity of caution when clinicians treat select patient groups with dupilumab for atopic dermatitis.